Archive · 3 Sep 2026
Cohance Lifesciences invests $18 million to expand ADC strategy
Cohance Lifesciences plans to spend $18 million on two biotechnology companies.
One of them is NJ Bio, where Cohance will increase its ownership.
The other is Aruka Bio, which works on a type of medicine called antibody-drug conjugates, or ADCs.
Cohance will become the controlling owner of Aruka Bio.
The companies want to combine research, customer services, and manufacturing.
This could help them develop medicines from early research through production.
The money will come from Cohance’s own funds.
The deals are expected to finish by September 2026 if all required agreements and conditions are met.
Cohance Lifesciences announced an $18 million investment to strengthen its antibody-drug conjugate strategy.
The company will invest $13 million in NJ Bio, raising its common-equity ownership from 56% to 67.3%.
A $5 million investment in Aruka Bio will give Cohance a 65% controlling stake.
The reorganization will integrate NJ Bio’s customer-facing services with Cohance’s manufacturing capabilities for end-to-end CRDMO development.
The transactions are expected to be completed by the end of September 2026, subject to agreements and customary closing conditions.
- Who
- Cohance Lifesciences, NJ Bio, and Aruka Bio.
- What
- Cohance announced $18 million in investments to expand its ADC strategy and increase ownership of both companies.
- When
- The announcement was published on September 3, 2026; completion is expected by the end of September 2026.
- Where
- Aruka Bio is based in Princeton; the articles do not specify where the transactions will be completed.
- Why
- The investments aim to strengthen ADC capabilities, integrate customer-facing services with manufacturing, and support end-to-end CRDMO development.
- Total investment
- USD 18 million
- Investment in NJ Bio
- USD 13 million
- NJ Bio ownership
- Cohance’s common-equity ownership will rise from 56% to 67.3%.
- Investment in Aruka Bio
- USD 5 million
- Aruka Bio ownership
- Cohance will hold a 65% controlling stake.
- Funding source
- Internal accruals
- Expected completion
- By the end of September 2026, subject to definitive agreements and customary closing conditions.